ADYX — Adynxx Share Price
Last Trade - 00:00- $0.25m
- $8.66m
- $0.46m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2014 | 2015 | 2016 | 2017 | 2018 | 2019E | 2020E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4.79 | 12.18 | 16.29 | 2.02 | 2.22 | 26.5 | 31.5 | 4.27% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Adynxx Inc., formerly Alliqua BioMedical, Inc., is a clinical stage biopharmaceutical company. The Company is focused on development of non-opioid therapeutics for the treatment of pain and inflammatory diseases. Its AYX platform utilizes a proprietary technology of non-opioid, disease-modifying transcription factor decoys. Its pipeline includes brivoligide and AYX2. Brivoligide product candidate is a potent and selective inhibitor of the transcription factor EGR1. Brivoligide is being developed for the prevention of post-surgical pain. AYX2 is a potent inhibitor of Kruppel-like Factors (KLF) six, nine and 15, transcription factors that maintain neuronal and glial activities involved in pain. AYX2 is being developed for the long-term suppression of chronic pain.
Directors
- Dennis Podlesak (62)
- Rick Orr
- Julien Mamet
- Donald Manning
- Stan Abel
- Gregory Flesher (49)
- Matthew Ruth
- Eckard Weber
- Last Annual
- December 31st, 2018
- Last Interim
- September 30th, 2019
- Incorporated
- April 15th, 2014
- Public Since
- May 25th, 2016
- No. of Shareholders
- 5,005,211
- No. of Employees
- 6
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 5,807,877
- Address
- 100 Pine St Ste 500, SAN FRANCISCO, 94111-5103
- Web
- https://ir.adynxx.com/
- Phone
- +1 4155127740
- Auditors
- Marcum LLP
Upcoming events for ADYX
Similar to ADYX
ADHERA THERAPEUTICS ORD
Pink Sheets on Nasdaq
ADVANTIS ORD
Pink Sheets on Nasdaq
AFFYMAX ORD
Pink Sheets on Nasdaq
AMARANTUS BIOSCIENCE HOLDINGS ORD
Pink Sheets on Nasdaq
AMERICAN CRYOSTEM ORD
Pink Sheets on Nasdaq
FAQ
As of Today at 20:44 UTC, shares in Adynxx are trading at $0.04. This share price information is delayed by 15 minutes.
Shares in Adynxx last closed at $0.04 and the price had moved by -69.71% over the past 365 days. In terms of relative price strength the Adynxx share price has underperformed the S&P500 Index by -76.57% over the past year.
The overall consensus recommendation for Adynxx is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Adynxx does not currently pay a dividend.
Adynxx does not currently pay a dividend.
Adynxx does not currently pay a dividend.
To buy shares in Adynxx you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.04, shares in Adynxx had a market capitalisation of $0.25m.
Here are the trading details for Adynxx:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ADYX
Based on an overall assessment of its quality, value and momentum Adynxx is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Adynxx is $2.80. That is 6503.77% above the last closing price of $0.04.
Analysts covering Adynxx currently have a consensus Earnings Per Share (EPS) forecast of -$1.17 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Adynxx. Over the past six months, its share price has underperformed the S&P500 Index by -87.96%.
As of the last closing price of $0.04, shares in Adynxx were trading -85.46% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Adynxx.
Adynxx's management team is headed by:
- Dennis Podlesak -
- Rick Orr -
- Julien Mamet -
- Donald Manning -
- Stan Abel -
- Gregory Flesher -
- Matthew Ruth -
- Eckard Weber -
We do not have data on Adynxx's shareholders